Familial hypercholesterolaemia: identification and management
KEYWORDS: people, healthcare, disease, therapy, coronary, healthcare professionals, professionals, children, heart disease, coronary heart, heart, concentration, risk, ldl-c, drug

and their parent or carer, and be informed by consideration of concomitant medication, comorbidities, safety and tolerability. [2008] 1.3.1.29 Healthcare professionals should consider offering fat-soluble vitamin (vitamins A, D and K) and folic acid supplementation for adults or children and young people with FH who are receiving long-term treatment with bile acid sequestrants (resins). [2008] 1.3.1.30 Healthcare professionals should offer people with FH a referral to a specialist with expertise in FH if they are experiencing side effects that compromise concordance with lipid-modifying drug therapy. [2008] 1.3.1.31 When the decision has been made to offer adults or children and young people with FH treatment with a statin, baseline liver and muscle enzymes (including transaminases and creatine kinase, respectively) should be measured before initiation of therapy. However, people with raised liver or muscle enzymes should not routinely be excluded from statin therapy. [2008] 1.3.1.32 Routine monitoring of creatine kinase is not recommended in asymptomatic adults or children and young people with FH who are receiving treatment with a statin. [2008] 1.3.2 Lifestyle interventions 1.3.2.1 Healthcare professionals should regard lifestyle advice as a component of medical management, and not as a substitute for lipid-modifying drug therapy. [2008] Diet 1.3.2.2 All people with
